Results 151 to 160 of about 20,539 (229)

Inhaled Nanomedicines for Lung Diseases and Injuries: Pharmacological Advances and Clinical Translation

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Graphical overview of bioinspired regenerative platforms designed to remodel the diseased lung microenvironment. These systems integrate gene addition, siRNA‐mediated transcript silencing, CRISPR‐based modulation, and base editing approaches to promote alveolar repair, AT2‐to‐AT1 regeneration, resolution of inflammation, and restoration of vascular ...
Kajal Kamra, Sonal Gaur, Jaswinder Singh
wiley   +1 more source

Adipose‐Derived Mesenchymal Stem Cells: Isolation, Origin, Phenotype Applications, and Challenges

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Bridging basic biology to clinical translation, this review systematically explores the in vivo origins and evolving isolation techniques of AD‐MSCs. We dissect their diverse phenotype applications orchestrated by immunometabolic reprogramming, mitochondrial transfer, and extracellular vesicles.
Ziyang Liu   +7 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Novel ZNFX1 Variants Associated With Refractory Anemia and Interstitial Lung Disease

open access: yesMolecular Genetics &Genomic Medicine, Volume 14, Issue 11, November 2026.
We identified three novel ZNFX1 variants in a child with refractory anemia and interstitial lung disease. Integrated transcriptomic, structural, and selected interferon‐stimulated gene expression analyses supported the molecular diagnosis and expanded the mutational and clinical spectrum of ZNFX1 deficiency, highlighting associated immune dysregulation.
Lu Jiang   +7 more
wiley   +1 more source

A Rare Endobronchial Lipoma of the Right Middle Lobe Causing Middle Lobe Syndrome and Recurrent Post‐Obstructive Infection in a Patient With Interstitial Lung Disease, Managed by Lung‐Sparing Bronchoscopy

open access: yesRespirology Case Reports, Volume 14, Issue 11, November 2026.
A 70‐year‐old smoker with combined pulmonary fibrosis and emphysema presented with recurrent right middle lobe infections and declining pulmonary function. This case describes bronchoscopic diagnosis of endobronchial lipoma and treatment of benign obstruction in persistent middle lobe disease, highlighting the need for longer surveillance to assess ...
Anastasios Palamidas   +4 more
wiley   +1 more source

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema

open access: yesRespirology, Volume 31, Issue 11, Page 1117-1125, November 2026.
This multicentre prospective study of 1016 patients demonstrated that CPFE, defined as ≥ 5% emphysema on visual CT assessment, identified a high‐risk phenotype with significantly worse 5‐year survival compared to non‐CPFE IIP patients (51.4% vs. 63.1%) and COPD patients (51.4% vs. 84.0%) and higher acute exacerbation incidence, validating international
Kazuya Tsubouchi   +23 more
wiley   +1 more source

CT‐Based Biomarkers for Predicting Progressive Phenotypes in Interstitial Lung Diseases: A Retrospective Cohort Study

open access: yesRespirology, Volume 31, Issue 11, Page 1134-1143, November 2026.
This study demonstrates that the Single Time Point Prediction score, a novel machine learning‐based imaging biomarker, along with established quantitative CT measures, is significantly associated with disease progression in non‐IPF ILD. This imaging metric may enable earlier identification of high‐risk patients and support personalised treatment ...
Ju Hyun Oh   +11 more
wiley   +1 more source

Multicenter Clinical Comparison Between Anti‐NXP2 and Anti‐TIF1‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies

open access: yesThe Journal of Dermatology, Volume 53, Issue 11, Page 1626-1637, November 2026.
ABSTRACT We aimed to measure anti‐nuclear matrix protein 2 antibody (anti‐NXP2) titers in patients with anti‐NXP2‐positive idiopathic inflammatory myopathies, investigate whether these titers are associated with clinical manifestations, malignancy risk, and treatment response, and compare the clinical and serological features between anti‐NXP2‐positive
Satoshi Kamiya   +15 more
wiley   +1 more source

T‐cell engagers in autoimmune rheumatic diseases: From concept to clinical practice

open access: yes
Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Christina Düsing   +2 more
wiley   +1 more source

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study

open access: yesAustralasian Journal of Dermatology, Volume 67, Issue 7, Page e431-e435, November 2026.
ABSTRACT This Australian retrospective cohort analysis of 1977 patients investigates and expands on correlates of telangiectasia in systemic sclerosis to determine whether this cutaneous sign is a potential surrogate marker for disease progression and prognosis.
Vivien Wai Yun Lai   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy